Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/MYC_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/MYC_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MYC_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MYC_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MYC_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MYC_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MYC_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MYC_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MYC_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MYC_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005067316 | Prostate | Tumor | epithelial cell proliferation | 125/3246 | 437/18723 | 2.56e-09 | 1.08e-07 | 125 |
GO:001095219 | Prostate | Tumor | positive regulation of peptidase activity | 68/3246 | 197/18723 | 4.09e-09 | 1.66e-07 | 68 |
GO:005067815 | Prostate | Tumor | regulation of epithelial cell proliferation | 110/3246 | 381/18723 | 1.32e-08 | 4.82e-07 | 110 |
GO:000989518 | Prostate | Tumor | negative regulation of catabolic process | 96/3246 | 320/18723 | 1.40e-08 | 5.07e-07 | 96 |
GO:007048218 | Prostate | Tumor | response to oxygen levels | 102/3246 | 347/18723 | 1.62e-08 | 5.75e-07 | 102 |
GO:002241118 | Prostate | Tumor | cellular component disassembly | 121/3246 | 443/18723 | 8.10e-08 | 2.23e-06 | 121 |
GO:003629318 | Prostate | Tumor | response to decreased oxygen levels | 94/3246 | 322/18723 | 8.37e-08 | 2.29e-06 | 94 |
GO:000166618 | Prostate | Tumor | response to hypoxia | 90/3246 | 307/18723 | 1.27e-07 | 3.28e-06 | 90 |
GO:004563719 | Prostate | Tumor | regulation of myeloid cell differentiation | 67/3246 | 210/18723 | 1.71e-07 | 4.25e-06 | 67 |
GO:190370617 | Prostate | Tumor | regulation of hemopoiesis | 103/3246 | 367/18723 | 1.78e-07 | 4.38e-06 | 103 |
GO:001095018 | Prostate | Tumor | positive regulation of endopeptidase activity | 58/3246 | 179/18723 | 6.35e-07 | 1.32e-05 | 58 |
GO:000176314 | Prostate | Tumor | morphogenesis of a branching structure | 62/3246 | 196/18723 | 6.78e-07 | 1.39e-05 | 62 |
GO:004328017 | Prostate | Tumor | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 45/3246 | 129/18723 | 1.17e-06 | 2.21e-05 | 45 |
GO:007121415 | Prostate | Tumor | cellular response to abiotic stimulus | 92/3246 | 331/18723 | 1.25e-06 | 2.32e-05 | 92 |
GO:010400415 | Prostate | Tumor | cellular response to environmental stimulus | 92/3246 | 331/18723 | 1.25e-06 | 2.32e-05 | 92 |
GO:190332214 | Prostate | Tumor | positive regulation of protein modification by small protein conjugation or removal | 47/3246 | 138/18723 | 1.50e-06 | 2.67e-05 | 47 |
GO:200057315 | Prostate | Tumor | positive regulation of DNA biosynthetic process | 28/3246 | 66/18723 | 1.57e-06 | 2.79e-05 | 28 |
GO:003220012 | Prostate | Tumor | telomere organization | 52/3246 | 159/18723 | 1.73e-06 | 3.05e-05 | 52 |
GO:006056214 | Prostate | Tumor | epithelial tube morphogenesis | 90/3246 | 325/18723 | 1.93e-06 | 3.34e-05 | 90 |
GO:006113813 | Prostate | Tumor | morphogenesis of a branching epithelium | 57/3246 | 182/18723 | 2.66e-06 | 4.45e-05 | 57 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513218 | Breast | Precancer | Salmonella infection | 49/684 | 249/8465 | 2.92e-09 | 6.15e-08 | 4.71e-08 | 49 |
hsa0516718 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0516918 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa0516618 | Breast | Precancer | Human T-cell leukemia virus 1 infection | 33/684 | 222/8465 | 4.29e-04 | 3.31e-03 | 2.53e-03 | 33 |
hsa0520514 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
hsa0516316 | Breast | Precancer | Human cytomegalovirus infection | 32/684 | 225/8465 | 1.13e-03 | 7.57e-03 | 5.80e-03 | 32 |
hsa0513219 | Breast | Precancer | Salmonella infection | 49/684 | 249/8465 | 2.92e-09 | 6.15e-08 | 4.71e-08 | 49 |
hsa0516719 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0516919 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa0516619 | Breast | Precancer | Human T-cell leukemia virus 1 infection | 33/684 | 222/8465 | 4.29e-04 | 3.31e-03 | 2.53e-03 | 33 |
hsa0520515 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
hsa0516317 | Breast | Precancer | Human cytomegalovirus infection | 32/684 | 225/8465 | 1.13e-03 | 7.57e-03 | 5.80e-03 | 32 |
hsa0513224 | Breast | IDC | Salmonella infection | 55/867 | 249/8465 | 2.07e-08 | 4.49e-07 | 3.36e-07 | 55 |
hsa0516922 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa0421824 | Breast | IDC | Cellular senescence | 35/867 | 156/8465 | 5.49e-06 | 7.43e-05 | 5.56e-05 | 35 |
hsa0520523 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0516723 | Breast | IDC | Kaposi sarcoma-associated herpesvirus infection | 38/867 | 194/8465 | 5.87e-05 | 5.96e-04 | 4.46e-04 | 38 |
hsa0516624 | Breast | IDC | Human T-cell leukemia virus 1 infection | 40/867 | 222/8465 | 2.52e-04 | 2.21e-03 | 1.66e-03 | 40 |
hsa0516324 | Breast | IDC | Human cytomegalovirus infection | 39/867 | 225/8465 | 6.66e-04 | 5.41e-03 | 4.05e-03 | 39 |
hsa0491916 | Breast | IDC | Thyroid hormone signaling pathway | 23/867 | 121/8465 | 2.45e-03 | 1.69e-02 | 1.27e-02 | 23 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MYC | SNV | Missense_Mutation | rs147506213 | c.697C>A | p.Pro233Thr | p.P233T | | protein_coding | tolerated(0.22) | benign(0.003) | TCGA-B6-A0I1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MYC | SNV | Missense_Mutation | | c.1291N>A | p.Glu431Lys | p.E431K | | protein_coding | tolerated(0.3) | benign(0.096) | TCGA-D8-A147-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
MYC | SNV | Missense_Mutation | | c.517G>C | p.Asp173His | p.D173H | | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MYC | insertion | Frame_Shift_Ins | novel | c.528_529insTATGA | p.Pro177TyrfsTer22 | p.P177Yfs*22 | | protein_coding | | | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD |
MYC | insertion | Frame_Shift_Ins | novel | c.530_531insTCGACTACGACTCGGTGCA | p.Asn178ArgfsTer86 | p.N178Rfs*86 | | protein_coding | | | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD |
MYC | SNV | Missense_Mutation | | c.482N>T | p.Ser161Leu | p.S161L | | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
MYC | SNV | Missense_Mutation | | c.986N>T | p.Ser329Phe | p.S329F | | protein_coding | tolerated(0.48) | possibly_damaging(0.622) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MYC | SNV | Missense_Mutation | | c.875N>T | p.Ser292Leu | p.S292L | | protein_coding | deleterious(0.04) | possibly_damaging(0.835) | TCGA-LP-A7HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MYC | SNV | Missense_Mutation | | c.482C>T | p.Ser161Leu | p.S161L | | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-A6-5659-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
MYC | SNV | Missense_Mutation | | c.470C>T | p.Ala157Val | p.A157V | | protein_coding | deleterious(0.03) | probably_damaging(0.99) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4609 | MYC | TRANSCRIPTION FACTOR, CLINICALLY ACTIONABLE | | BAY1000394 | | |
4609 | MYC | TRANSCRIPTION FACTOR, CLINICALLY ACTIONABLE | | ORNITHINE DECARBOXYLASE INHIBITOR | | 11876528 |
4609 | MYC | TRANSCRIPTION FACTOR, CLINICALLY ACTIONABLE | | PROTEASOME INHIBITOR | | 16186809 |
4609 | MYC | TRANSCRIPTION FACTOR, CLINICALLY ACTIONABLE | | HISTONE DEACETYLASE INHIBITOR | | 15474507 |
4609 | MYC | TRANSCRIPTION FACTOR, CLINICALLY ACTIONABLE | | FOLIC ACID | | 3479800 |
4609 | MYC | TRANSCRIPTION FACTOR, CLINICALLY ACTIONABLE | | GLN | GLUTAMINE | 16898871 |
4609 | MYC | TRANSCRIPTION FACTOR, CLINICALLY ACTIONABLE | | AN-9 | AN-9 | 8348968 |
4609 | MYC | TRANSCRIPTION FACTOR, CLINICALLY ACTIONABLE | | PROTOPORPHYRIN | PROTOPORPHYRIN | 9868803 |
4609 | MYC | TRANSCRIPTION FACTOR, CLINICALLY ACTIONABLE | | POH | | 16439861 |
4609 | MYC | TRANSCRIPTION FACTOR, CLINICALLY ACTIONABLE | | HYPOXANTHINE | HYPOXANTHINE | 3528863 |